##  [Positions](/node/639291 "Positions") 

  



 Access

  

- [Access to medicines (PDF 0.2 MB)](/sites/novartis_com/files/access-to-medicines.pdf "access-to-healthcare-perspective.pdf")



 

 

 



 



 R&D



  

- [Animal research (PDF 0.2 MB)](/sites/novartis_com/files/animal-research.pdf "animal-research.pdf")
- [Clinical study transparency (PDF 0.2 MB)](/sites/novartis_com/files/clinical-trial-data-transparency.pdf "clinical-trial-data-transparency.pdf")
- [Medicines for Patients with Rare Diseases (PDF 0.2 MB)](/sites/novartis_com/files/medicines-for-patients-with-rare-diseases.pdf "medicines-for-patients-with-rare-diseases.pdf")
- [Post-trial Access (PDF 0.1 MB)](/sites/novartis_com/files/novartis-position-on-post-trial-access.pdf "novartis-position-on-post-trial-access.pdf")
- [Novartis Position on Access to Unauthorized Novartis Products through Managed Access Programs (MAPs) (PDF 0.2 MB)](/sites/novartis_com/files/novartis-position-unauthorized-products-access.pdf "novartis-position-unauthorized-products-access.pdf")
- [Responsible Clinical Trials (PDF 0.1 MB)](/sites/novartis_com/files/novartis-position-on-responsible-clinical-trials.pdf "novartis-position-on-responsible-clinical-trials.pdf")
- [Novartis Commitment to Diversity in Clinical Trials (PDF 0.2 MB)](/sites/novartis_com/files/commitment-for-diversity-in-clinical-trials.pdf "commitment-for-diversity-in-clinical-trials.pdf")
- [Novartis Position on Investigator Initiated Trials (IITs) and Investigator Initiated Research (IIRs) (PDF 0.2 MB)](/sites/novartis_com/files/novartis-investigator-initiated-trials.pdf "novartis-investigator-initiated-trials.pdf")
- [Position on Scientific Publications (PDF 0.2 MB)](/sites/novartis_com/files/position-on-scientific-publications.pdf "novartis-publication-guidelines-posting.pdf")



 

 

 



 



 Quality and safety of medicines



  

- [Falsified Medical Products (PDF 0.3 MB)](/sites/novartis_com/files/novartis-position-on-falsified-medical-products.pdf "novartis-position-on-falsified-medical-products.pdf")



 

 

 



 



 Intellectual property



  

- [Intellectual Property (PDF 0.3 MB)](/sites/novartis_com/files/novartis-intellectual-property-position.pdf "novartis-intellectual-property-position.pdf")
- [Regulatory data protection (PDF 0.3 MB)](/sites/novartis_com/files/regulatory-data-protection.pdf "regulatory-data-protection.pdf")



 

 

 



 



 Ethics



  

- [Novartis Position on Collaborating with Patient Organizations (PDF 0.2 MB)](/sites/novartis_com/files/novartis-position-on-collaborating-with-patient-organizations.pdf "novartis-position-on-collaborating-with-patient-organizations.pdf")



 

 

 



 



 Environment



  

- [Pharmaceuticals in the environment (PDF 0.2 MB)](/sites/novartis_com/files/pharmaceuticals-environment.pdf "pharmaceuticals-environment.pdf")



 

 

 



 



 Taxation



  

- [Novartis Tax Policy Statement (PDF 0.2 MB)](/sites/novartis_com/files/tax-policy-statement.pdf "tax-policy-statement.pdf")



 

 

 



 



 

 





 



- [Print](/node/639291/printable/print)
- [PDF](/node/639291/printable/pdf)